Advertisement

Topics

BioDevelops Pharma GmbH Company Profile

16:28 EDT 22nd September 2018 | BioPortfolio

BioDevelops, an independent Austrian company, was initially founded back in 2002 and first concentrated on biomarker applications. Due to an opportunity to engage in the development of a clinical Phase II product with AOP Orphan Pharmaceuticals, the company changed its focus early in 2004 and entered the Cystic Fibrosis arena.Following successful turnaround, BioDevelops started its research operations a few months later at the Institute for Pharmacology in Vienna and focused on strategies for treatment of cystic fibrosis. In Sept. 2004, the Medical University of Vienna sold respective IP rights to BioDevelops. Consequently, the company filed a US-patent for an approach to enhance cell surface expression of proteins targeting Protein-Folding Diseases. The preliminary data - obtained with the A2A-receptor - were later supported with experimental findings on CFTR, the protein which is mutated in cystic fibrosis. The underlying research has been published recently (for full paper see T. Milojevic; for review see M. Toews). In addition to the IP transfer, the University granted to BioDevelops a right of first refusal for all IP related to the content of the original patent. Accordingly, BioDevelops also exerted its prerogative in sponsoring the July 2005 submission of a “second medical use” patent for proteasome inhibitors in the treatment of cystic fibrosis.

Location

c/o Institute for PharmacologyWaehringer Strasse 13A
Vienna
1090
Austria

Contact

Phone: 43.1.710.6616
Fax: 43.1.710.6614
Email: board@biodevelops.com


News Articles [737 Associated News Articles listed on BioPortfolio]

DGAP-News: Novartis Pharma GmbH: GET.ON, TelePark und Circumradius gewinnen Digitalen Gesundheitspreis von Novartis und Sandoz

Novartis Pharma GmbH: GET.ON, TelePark und Circumradius gewinnen Digitalen Gesundheitspreis von Novartis und Sandoz Deutschland/Hexal DGAP-News: Novartis Pharma GmbH / Schlagwort(e): Sonstiges Nov...

Merz Pharma GmbH Co. KGaA Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 26062018] Prices from USD $350

Merz Pharma GmbH Co. KGaA Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Merz Pharma GmbH Co. KGaA Mergers Acquisitions MA, Partnerships Alliances and ...

DGAP-Adhoc: CO.DON AG: CO.DON AG zeichnet Term Sheet mit der Haemo Pharma GmbH über den Vertrieb von Spherox in Österreich (deutsch)

CO.DON AG: CO.DON AG zeichnet Term Sheet mit der Haemo Pharma GmbH über den Vertrieb von Spherox in Österreich DGAP-Ad-hoc: CO.DON AG / Schlagwort(e): Markteinführung CO.DON AG: CO.DON AG zeichnet....

Systec GmbH Introduces its new Business Partner Evidencia GmbH

Research, pharmaceuticals, life sciences and food: many laboratories rely on steam sterilizers or equipment where processes are monitored using pressure and temperature control. Thanks to our collabor...

Royalties under patent licence agreements: can they remain payable even if the licensed patents(s) are revoked or not practised? Lessons from Genentech Inc v Hoechst GmbH & Sanofi-Aventis Deutschland GmbH

Précis In its recent decision in Genentech Inc v Hoechst GmbH & Sanofi-Aventis Deutschland GmbH (7 July 2016), the Court of Justice of the EU (“CJEU”) has ruled that an obligati...

Laufende Fusionskontrollverfahren: Bruker Daltonik GmbH, Bremen (D); Erwerb einer Mehrheitsbeteiligung von 80% an der HAIN LIFESCIENCE GmbH, Nehren (D);

Datum der Anmeldung:28.08.2018Aktenzeichen:B3-128/18Unternehmen:Bruker Daltonik GmbH, Bremen (D); Erwerb einer Mehrheitsbeteiligung von 80% an der HAIN LIFESCIENCE GmbH, Nehren (D);Produktmärkte:in.....

Laufende Fusionskontrollverfahren: The Paragon Fund II GmbH & Co. KG, München (D); mittelbarer Erwerb von mindestens 99% der Anteile sowie der Kontrolle über die UCB Innere Medizin GmbH & Co. KG, Monheim (D) und die UCB Primary Care GmbH, Monheim (D);

Datum der Anmeldung:07.08.2018Aktenzeichen:B3-119/18Unternehmen:The Paragon Fund II GmbH & Co. KG, München (D); mittelbarer Erwerb von mindestens 99% der Anteile sowie der Kontrolle über die UCB In....

Original-Research: CO.DON AG (von Sphene Capital GmbH): Buy

Original-Research: CO.DON AG - von Sphene Capital GmbH Einstufung von Sphene Capital GmbH zu CO.DON AG Unternehmen: CO.DON AG ISIN: DE000A1K0227 Anlass der Studie: Update Report Empfehlung: Buy se...

PubMed Articles [30 Associated PubMed Articles listed on BioPortfolio]

Cost-effectiveness analysis of blue light cystoscopy with hexylaminolevulinate in transurethral resection of the bladder.

Photodynamic diagnosis using the optical imaging agent hexaminolevulinate (HAL, Hexvix®, Ipsen Pharma GmbH, Ettlingen, Germany) as an adjunct to white light cystoscopy (WLC) during the initial transu...

Data and Corporate Governance in Pharma and Digital Health: A Necessary Regulatory Convergence.

Data and Corporate Governance in Pharma and Digital Health: A Necessary Regulatory Convergence.

Clinical trials go virtual, big pharma dives in.

Correction to: Lonoctocog Alfa: A Review in Haemophilia A.

The article Lonoctocog Alfa: A Review in Haemophilia A, written by Zaina T. Al-Salama and Lesley J. Scott, was originally published Online First without open access. After publication in volume 77...

21 Century Citizen Pharma: The FDA & Patient-Focused Product Development.

Perpetual debate regarding the delicate balance between access and innovation and the protection of the public health and safety dominate discussions of the United States Food and Drug Administration ...

Clinical Trials [120 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Linagliptin from Prevaglip 5 mg tablets(Eva pharma for Pharmaceuticals & Me...

Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h)

The present clinical trial will be conducted in order to compare the bioavailability of rivastigmine and to assess bioequivalence at steady-state of the Test product RID-TDS 9.5 mg/24 h (L...

Pharmacokinetic Drug Interaction Between Ezetimibe and Sirolimus After Single Dose Administration in Healthy Subjects

The purpose of this study is to confirm a significant influence of ezetimibe and sirolimus on each others pharmacokinetics

A Bioequivalence Study of Isosorbide-5-Mononitrate Extended-Release Tablets Under Fed Conditions in Healthy Subjects

The purpose of this trial is to compare the pharmacokinetic characteristics of two isosorbide -5 -mononitrate extended -release tablets 40 mg of Qilu Pharmaceutical Co., Ltd and ISMO Retar...

Fasting Bioequivalence Study of Memantinol 20 mg Tablets Versus Akatinol Memantine® 20 mg Tablets In Normal Healthy Subjects

This study are two-way crossover, open-label, single-dose, fasting, bioequivalence study of Memantinol® (JSC "GEROPHARM", Russia) 20 mg tablets versus Akatinol Memantine® (Merz Pharma Gm...

Companies [1261 Associated Companies listed on BioPortfolio]

BioDevelops Pharma GmbH

BioDevelops, an independent Austrian company, was initially founded back in 2002 and first concentrated on biomarker applications. Due to an opportunity to engage in the development of a clinical Phas...

Chemie-Kontor GmbH

Chemie-Kontor GmbH trades with chemical specialities for customers in Pharma-, Agro-, Cosmetics and Nutrition Industries and offers a broad range of services. Chemie-Kontor GmbH is agent for: Amberger...

INJEX Pharma AG

INJEX Pharma Aktiengesellschaft and its subsidiaries INJEX Pharma GmbH and INJEX Vertrieb Deutschland GmbH are specialized in the development, manufacturing and marketing in the m...

CROMA-PHARMA GmbH

CROMA-PHARMA is a family owned, internationally orientated pharmaceutical company, based in Korneuburg, Austria. CROMA-PHARMA´s areas of activity are orthopedics, ophthalmology...

Ratiopharm

On June 29, 2000, ratiopharm GmbH, Europe's largest generic drug company, purchased Technilab Pharma to establish ratiopharm's generic operations in Canada. Long before being acquired by ratiopharm Gm...

More Information about "BioDevelops Pharma GmbH" on BioPortfolio

We have published hundreds of BioDevelops Pharma GmbH news stories on BioPortfolio along with dozens of BioDevelops Pharma GmbH Clinical Trials and PubMed Articles about BioDevelops Pharma GmbH for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BioDevelops Pharma GmbH Companies in our database. You can also find out about relevant BioDevelops Pharma GmbH Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Cystic Fibrosis
Affecting over 8,500 people in the UK, Cystic Fibrosis (CF) is one of the UK's most common life-threatening inherited diseases. Around half of the CF population can expect to live over 38 years, although improvements in treatments mean a baby born ...

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...


Corporate Database Quicklinks



Searches Linking to this Company Record